Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2181-2190 Newer>

The Motley Fool July 18, 2005 VB Rosendahl	Profit From a Secure Homeland Project BioShield is opening up new possibilities for small biotechs. Should investors take notice?
The Motley Fool July 18, 2005 Stephen D. Simpson	Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky.
The Motley Fool July 18, 2005 Karl Thiel	Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note.
BusinessWeek July 25, 2005 Gene G. Marcial	Spectrum's Cancer Drugs Could be Winners Biotechs got battered earlier this year, but some investors are optimistic about Spectrum Pharmaceuticals because of the anticancer agents it has in advanced clinical trials.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
The Motley Fool July 12, 2005 T.G. Wolf	Horizon's Future Looks Bright Getting back to basics pays off for the health care company. Investors, take note.
<Older 2181-2190 Newer> Return to current articles.